TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL VACCINE TECHNOLOGIES MARKET, BY TYPE
6.1. Overview
6.2. Recombinant/Conjugate/Subunit
6.3. Inactivated
6.4. Live Attenuated
6.5. Toxoid
7. GLOBAL VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Parenteral
7.3. Oral
8. GLOBAL VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION
8.1. Overview
8.2. Viral Diseases
8.3. Bacterial Diseases
9. GLOBAL VACCINE TECHNOLOGIES MARKET, BY AGE GROUP
9.1. Overview
9.2. Pediatric
9.3. Adults
10. GLOBAL VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL
10.1. Overview
10.2. Hospital & Retail Pharmacies
10.3. Government Suppliers
10.4. Others
11. GLOBAL VACCINE TECHNOLOGIES MARKET, BY REGION
11.1. Overview
11.2. North America
11.2.1. U.S.
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. U.K
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. South Korea
11.4.5. Australia
11.4.6. Rest of Asia-Pacific
11.5. Rest of the World
11.5.1. Middle East
11.5.2. Africa
11.5.3. Latin America
12. COMPETITIVE LANDSCAPE
12.1. Overview
12.2. Competitive Analysis
12.3. Market Share Analysis
12.4. Major Growth Strategy in the Global Vaccine technologies Market,
12.5. Competitive Benchmarking
12.6. Leading Players in Terms of Number of Developments in the Global Vaccine technologies Market,
12.7. Key developments and Growth Strategies
12.7.1. New Type Launch/Route of Administration Deployment
12.7.2. Merger & Acquisitions
12.7.3. Joint Ventures
12.8. Major Players Financial Matrix
12.8.1. Sales & Operating Income, 2022
12.8.2. Major Players R&D Expenditure. 2022
13. COMPANY PROFILES
13.1. GLAXOSMITHKLINE PLC. (BRENTFORD, U.K.)
13.1.1. Company Overview
13.1.2. Financial Overview
13.1.3. Types Offered
13.1.4. Key Developments
13.1.5. SWOT Analysis
13.1.6. Key Strategies
13.2. Sanofi (Paris, France)
13.2.1. Company Overview
13.2.2. Financial Overview
13.2.3. Types Offered
13.2.4. Key Developments
13.2.5. SWOT Analysis
13.2.6. Key Strategies
13.3. Pfizer Inc. (New York, U.S.)
13.3.1. Company Overview
13.3.2. Financial Overview
13.3.3. Types Offered
13.3.4. Key Developments
13.3.5. SWOT Analysis
13.3.6. Key Strategies
13.4. Merck & Co., Inc. (New Jersey, U.S.)
13.4.1. Company Overview
13.4.2. Financial Overview
13.4.3. Types Offered
13.4.4. Key Developments
13.4.5. SWOT Analysis
13.4.6. Key Strategies
13.5. Novartis AG (Basel, Switzerland)
13.5.1. Company Overview
13.5.2. Financial Overview
13.5.3. Types Offered
13.5.4. Key Developments
13.5.5. SWOT Analysis
13.5.6. Key Strategies
13.6. EMERGENT BIOSOLUTIONS, INC. (MARYLAND, U.S.)
13.6.1. Company Overview
13.6.2. Financial Overview
13.6.3. Types Offered
13.6.4. Key Developments
13.6.5. SWOT Analysis
13.6.6. Key Strategies
13.7. CSL Limited (Melbourne, Australia)
13.7.1. Company Overview
13.7.2. Financial Overview
13.7.3. Types Offered
13.7.4. Key Developments
13.7.5. SWOT Analysis
13.7.6. Key Strategies
13.8. Inovio Pharmaceuticals, Inc. (Pennsylvania, U.S.)
13.8.1. Company Overview
13.8.2. Financial Overview
13.8.3. Types Offered
13.8.4. Key Developments
13.8.5. SWOT Analysis
13.8.6. Key Strategies
13.9. Bavarian Nordic (Denmark)
13.9.1. Company Overview
13.9.2. Financial Overview
13.9.3. Types Offered
13.9.4. Key Developments
13.9.5. SWOT Analysis
13.9.6. Key Strategies
13.10. Mitsubishi Tanabe Pharma Corporation (Osaka, Japan)
13.10.1. Company Overview
13.10.2. Financial Overview
13.10.3. Types Offered
13.10.4. Key Developments
13.10.5. SWOT Analysis
13.10.6. Key Strategies
14. APPENDIX
14.1. References
14.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL VACCINE TECHNOLOGIES MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL VACCINE TECHNOLOGIES MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 5 GLOBAL VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 6 GLOBAL VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 7 GLOBAL VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 8 NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 9 NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 10 NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 11 NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 12 NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 13 NORTH AMERICA VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 14 U.S. VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 15 U.S. VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 16 U.S. VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 17 U.S. VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 18 U.S. VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 19 CANADA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 20 CANADA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 21 CANADA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 22 CANADA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 23 CANADA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 24 EUROPE VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 25 EUROPE VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 26 EUROPE VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 27 EUROPE VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 28 EUROPE VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 29 EUROPE VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 30 GERMANY VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 31 GERMANY VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 32 GERMANY VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 33 GERMANY VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 34 GERMANY VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 35 FRANCE VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 36 FRANCE VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 37 FRANCE VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 38 FRANCE VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 39 FRANCE VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 40 U.K VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 41 U.K VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 42 U.K VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 43 U.K VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 44 U.K VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 45 ITALY VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 46 ITALY VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 47 ITALY VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 48 ITALY VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 49 ITALY VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 50 SPAIN VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 51 SPAIN VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 52 SPAIN VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 53 SPAIN VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 54 SPAIN VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 55 REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 56 REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 57 REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 58 REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 59 REST OF EUROPE VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 60 ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 61 ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 62 ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 63 ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 64 ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 65 ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 66 CHINA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 67 CHINA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 68 CHINA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 69 CHINA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 70 CHINA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 71 JAPAN VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 72 JAPAN VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 73 JAPAN VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 74 JAPAN VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 75 JAPAN VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 76 INDIA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 77 INDIA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 78 INDIA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 79 INDIA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 80 INDIA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 81 SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 82 SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 83 SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 84 SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 85 SOUTH KOREA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 86 AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 87 AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 88 AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 89 AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 90 AUSTRALIA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 91 REST OF ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 92 REST OF ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 93 REST OF ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 94 REST OF ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 95 REST OF ASIA PACIFIC VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 96 REST OF THE WORLD VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 97 REST OF THE WORLD VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 98 REST OF THE WORLD VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 99 REST OF THE WORLD VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 100 REST OF THE WORLD VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 101 REST OF THE WORLD VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2018-2032 (USD BILLION)
TABLE 102 MIDDLE EAST VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 103 MIDDLE EAST VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 104 MIDDLE EAST VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 105 MIDDLE EAST VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 106 MIDDLE EAST VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 107 AFRICA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 108 AFRICA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 109 AFRICA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 110 AFRICA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 111 AFRICA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 112 LATIN AMERICA VACCINE TECHNOLOGIES MARKET, BY TYPE, 2018-2032 (USD BILLION)
TABLE 113 LATIN AMERICA VACCINE TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 114 LATIN AMERICA VACCINE TECHNOLOGIES MARKET, BY DISEASE INDICATION, 2018-2032 (USD BILLION)
TABLE 115 LATIN AMERICA VACCINE TECHNOLOGIES MARKET, BY AGE GROUP, 2018-2032 (USD BILLION)
TABLE 116 LATIN AMERICA VACCINE TECHNOLOGIES MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VACCINE TECHNOLOGIES MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VACCINE TECHNOLOGIES MARKET
FIGURE 4 GLOBAL VACCINE TECHNOLOGIES MARKET, SHARE (%), BY TYPE, 2022
FIGURE 5 GLOBAL VACCINE TECHNOLOGIES MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2022
FIGURE 6 GLOBAL VACCINE TECHNOLOGIES MARKET, SHARE (%), BY DISEASE INDICATION, 2022
FIGURE 7 GLOBAL VACCINE TECHNOLOGIES MARKET, SHARE (%), BY AGE GROUP, 2022
FIGURE 8 GLOBAL VACCINE TECHNOLOGIES MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022
FIGURE 9 GLOBAL VACCINE TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 NORTH AMERICA: VACCINE TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 EUROPE: VACCINE TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 ASIA-PACIFIC: VACCINE TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
FIGURE 13 REST OF THE WORLD: VACCINE TECHNOLOGIES MARKET, SHARE (%), BY REGION, 2022
FIGURE 14 GLOBAL VACCINE TECHNOLOGIES MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 15 GLAXOSMITHKLINE PLC. (BRENTFORD, U.K.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 GLAXOSMITHKLINE PLC. (BRENTFORD, U.K.): SWOT ANALYSIS
FIGURE 17 SANOFI (PARIS, FRANCE): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 SANOFI (PARIS, FRANCE): SWOT ANALYSIS
FIGURE 19 PFIZER INC. (NEW YORK, U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 PFIZER INC. (NEW YORK, U.S.): SWOT ANALYSIS
FIGURE 21 MERCK & CO., INC. (NEW JERSEY, U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 MERCK & CO., INC. (NEW JERSEY, U.S.): SWOT ANALYSIS
FIGURE 23 NOVARTIS AG (BASEL, SWITZERLAND).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 NOVARTIS AG (BASEL, SWITZERLAND).: SWOT ANALYSIS
FIGURE 25 EMERGENT BIOSOLUTIONS, INC. (MARYLAND, U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 EMERGENT BIOSOLUTIONS, INC. (MARYLAND, U.S.): SWOT ANALYSIS
FIGURE 27 CSL LIMITED (MELBOURNE, AUSTRALIA): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 CSL LIMITED (MELBOURNE, AUSTRALIA): SWOT ANALYSIS
FIGURE 29 INOVIO PHARMACEUTICALS, INC. (PENNSYLVANIA, U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 INOVIO PHARMACEUTICALS, INC. (PENNSYLVANIA, U.S.): SWOT ANALYSIS
FIGURE 31 BAVARIAN NORDIC (DENMARK): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 BAVARIAN NORDIC (DENMARK): SWOT ANALYSIS
